Novartis AG (ETR:NOT)
Germany · Delayed Price · Currency is EUR | Market Cap | 260.48B +19.3% |
| Revenue (ttm) | 49.62B +2.7% |
| Net Income | 11.17B -6.6% |
| EPS | 5.77 -3.4% |
| Shares Out | n/a |
| PE Ratio | 23.74 |
| Forward PE | 16.51 |
| Dividend | 4.10 (2.99%) |
| Ex-Dividend Date | Mar 10, 2026 |
| Volume | 2,786 |
| Open | 136.56 |
| Previous Close | 136.48 |
| Day's Range | 136.02 - 137.28 |
| 52-Week Range | 104.52 - 144.12 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 27, 2026 |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial numbers in USD Financial StatementsNews
Novartis (NVS) Gains European Commission Approval for Cosentyx in Polymyalgia Rheumatica
Novartis (NVS) Gains European Commission Approval for Cosentyx in Polymyalgia Rheumatica
Novartis announces European Commission approval for Cosentyx in PMR
Novartis (NVS) announced that the European Commission has approved Cosentyx for the treatment of adults with polymyalgia rheumatica, or PMR, who have had an inadequate response to glucocorticoids or w...
Novartis (NVS) Gains FDA Orphan Designation for Rapcabtagene Autoleucel in Rare Muscle Disorders
Novartis (NVS) Gains FDA Orphan Designation for Rapcabtagene Autoleucel in Rare Muscle Disorders
Novartis treatment of idiopathic inflammatory myopathies gets orphan designation
Novartis (NVS)’ rapcabtagene autoleucel received FDA orphan designation for treatment of idiopathic inflammatory myopathies, according to a post to the agency’s website.
Novartis treatment of idiopathic inflammatory myopathies gets orphan designation
Novartis (NVS)’ rapcabtagene autoleucel received FDA orphan designation for treatment of idiopathic inflammatory myopathies gets orphan designation, according to a post to the agency’s website.
Women see five or six doctors to figure out menopause symptoms. A top Novartis exec says AI could finally connect the dots
At Fortune’s MPW Summit, top health care leaders said midlife care is too fragmented, and AI could help women put the pieces together.
Novartis terminates mid-stage trial of lupus nephritis treatment, Endpoints says
Novartis (NVS) has scrapped a mid-stage trial of Fabhalta in lupus nephritis, citing “strategic considerations,” Endpoints News’ Lei Lei Wu reports, citing a federal clinical trials database. Publishe...
Novartis ends mid-stage Fabhalta trial targeting serious kidney condition
Swiss drugmaker Novartis has terminated a mid-stage study testing its drug Fabhalta in patients with a serious kidney condition, citing "strategic considerations", according to a federal clinical tr...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG ("Novartis" or the "Company") (NYSE: NVS). Such investors are advised to contact Dan...
Novartis AG (NVS) Stock Up 3.1% but GF Value Says Overvalued -- GF Score: 68/100
Novartis AG (NVS) Stock Up 3.1% but GF Value Says Overvalued -- GF Score: 68/100
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG (“Novartis” or the “Company”) (NYSE: NVS). Such investors are advised to contac...
Novartis (NVS) Gains FDA Approval for Lamprene, Enhancing Patient Access
Novartis (NVS) Gains FDA Approval for Lamprene, Enhancing Patient Access
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG ("Novartis" or the "Company") (NYSE: NVS). Such investors are advised to contact Dan...
Novartis Wins FDA Approval For First Symptomatic Dermographism Treatment
(RTTNews) - Novartis (NVS) announced Wednesday that the U.S. FDA has approved Rhapsido for adults with symptomatic dermographism whose symptoms remain inadequately controlled by H1 antihistamines. The...
Novartis (NVS) Secures FDA Approval for Rhapsido, Expanding Treatment Options for Chronic Hives
Novartis (NVS) Secures FDA Approval for Rhapsido, Expanding Treatment Options for Chronic Hives
US FDA expands use of Novartis drug for chronic skin condition
The US Food and Drug Administration has expanded the use of Novartis' drug to treat adults with a chronic skin condition that causes recurring itchy welts, the Swiss drugmaker said on Wednesday.
Novartis announces FDA approval of Rhapsido for symptomatic dermographism
Novartis (NVS) announced that the Food and Drug Administration approved Rhapsido as the first treatment for adults with symptomatic dermographism inadequately controlled by H1 antihistamines. Rhapsido...
Novartis to present data from MS portfolio with 46 abstracts at MSToronto2026
Novartis (NVS) will present new data from its multiple sclerosis, MS, portfolio with 46 abstracts at MSToronto2026, the 10th Joint ACTRIMS-ECTRIMS Meeting. Among these is a late-breaking abstract feat...
Focus: AI companies run virtual drug trials, aim to improve success of human studies
Novartis' experimental del-desiran for a rare type of muscular dystrophy was expected to be a winner, with the Swiss company's CEO predicting annual peak sales of $5 billion. When a late-stage trial m...
Novartis Stocks Stay Flat as $575 Million RNA Bet Opens $7.2 Billion Tail
Novartis Stocks Stay Flat as $575 Million RNA Bet Opens $7.2 Billion Tail
Novartis price target lowered to $156 from $170 at Morgan Stanley
Morgan Stanley analyst Thibault Boutherin lowered the firm’s price target on Novartis (NVS) to $156 from $170 and keeps an Overweight rating on the shares. The firm lowered the price…
Novartis Signs Deal With Abogen For MRNA Therapies
(RTTNews) - Swiss pharmaceutical company Novartis AG (NVS) announced it has entered into a licensing and option agreement with China-based Abogen Biosciences to develop mRNA-encoded therapies, includi...
Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
Swiss Novartis is entering a licensing agreement with a Chinese biotech worth as much as $7.8 billion. It comes after several pharma peers announced deals with China-based drug developers over the pas...
Novartis to License Drug From China's Abogen in Up to $7.8 Billion Deal
Abogen said its lead drug has potential to transform the treatment landscape for patients with autoimmune diseases.
Novartis (NVS) Secures $575M Licensing Deal with Abogen Biosciences for Innovative mRNA Therapy
Novartis (NVS) Secures $575M Licensing Deal with Abogen Biosciences for Innovative mRNA Therapy